Antagonism of bromocriptine-induced cage climbing behaviour in mice by the selective D-2 dopamine receptor antagonists, metoclopramide and molindone.
Bromocriptine (5-30 mg/kg, ip), 2 hr after administration, induced cage climbing behaviour in mice. Pretreatment with haloperidol, an antagonist of both D-1 and D-2 dopamine receptors, metoclopramide and molindone, the selective D-2 dopamine receptor antagonists, effectively antagonised bromocriptine-induced climbing behaviour. The results indicate that bromocriptine most probably induces climbing behaviour in mice by stimulating the postsynaptic striatal D-2 dopamine receptors.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001971:Bromocriptine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D051379:Mice; D008972:Molindone / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D011954:Receptors, Dopamine / Q000187:drug effects; D017448:Receptors, Dopamine D2
D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D001971:Bromocriptine; D006220:Haloperidol; D008787:Metoclopramide; D008972:Molindone